Entrada Therapeutics (TRDA) Accumulated Expenses (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Accumulated Expenses of $11.7 million for Q1 2026, up 54.77% year-over-year from $7.6 million in Q1 2025, and down 33.66% quarter-over-quarter from $17.7 million in Q4 2025.
Entrada Therapeutics (TRDA) Accumulated Expenses (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $11.7 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 54.77% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $11.7 million (up 54.77% YoY), while the FY2025 annual figure was $17.7 million, up 32.52% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $11.7 million, down from $17.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $17.7 million in Q4 2025, with the low at $4.5 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $11.3 million (2023), against an average of $10.6 million.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses jumped 158.09% in 2023, then dropped 24.7% in 2024.
- Entrada Therapeutics' Accumulated Expenses stood at $7.6 million in 2022, then jumped by 49.49% to $11.3 million in 2023, then climbed by 17.82% to $13.3 million in 2024, then soared by 32.52% to $17.7 million in 2025, then plunged by 33.66% to $11.7 million in 2026.
- Business Quant data shows TRDA's Accumulated Expenses at $11.7 million in Q1 2026, $17.7 million in Q4 2025, and $15.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.00 Mn |
| Mar 31, 2026 | 11.73 Mn |
| Dec 31, 2025 | 17.68 Mn |
| Sep 30, 2025 | 15.53 Mn |
| Jun 30, 2025 | 11.80 Mn |
| Mar 31, 2025 | 7.58 Mn |
| Dec 31, 2024 | 13.34 Mn |
| Sep 30, 2024 | 13.40 Mn |
| Jun 30, 2024 | 11.00 Mn |
| Mar 31, 2024 | 8.79 Mn |
| Dec 31, 2023 | 11.33 Mn |
| Sep 30, 2023 | 9.60 Mn |
| Jun 30, 2023 | 7.11 Mn |
| Mar 31, 2023 | 11.68 Mn |
| Dec 31, 2022 | 7.58 Mn |
| Sep 30, 2022 | 11.95 Mn |
| Jun 30, 2022 | 5.34 Mn |
| Mar 31, 2022 | 4.52 Mn |
| Dec 31, 2021 | 6.01 Mn |
| Sep 30, 2021 | 4.88 Mn |